[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100311460":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":10,"centralContacts":42,"locations":51,"responsibleParty":203,"collaborators":205,"id":211,"slug":212,"hasResults":213,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":10,"eligibilityCriteria":217,"healthyVolunteers":218,"sex":219,"minAge":220,"maxAge":10,"enrollmentInfo":221,"targetDuration":10,"studyType":224,"phases":10,"briefSummary":225,"conditions":226,"keywords":231,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,15,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Locally Advanced or Metastatic Pancreatic Cancer Cohort",null,"For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.",[13,14],"Diagnostic Test: Blood Draw","Diagnostic Test: Tumor Tissue Collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Acute Benign Pancreatic Pathology Control Cohort","For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl","For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.",[13,14,23],"Diagnostic Test: Cyst Fluid",{"label":25,"type":10,"description":26,"interventionNames":27},"Healthy Control","For normal controls, blood specimens will be drawn once at study baseline.",[13],[29,34,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DIAGNOSTIC_TEST","Blood Draw","If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:\n\nPatients and controls weighing 50kg or more\n\n* For draw amounts up to 50mL, there is no required hemoglobin threshold.\n* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day\u002Feight week period.\n\nPatients and controls weighing \\\u003C 50kg\n\n* For patients whose hemoglobin is below normal limits but at least 7.0 gm\u002FdL, no more than a total of 50 ml of blood or 5 ml\u002Fkg, whichever is less, may be collected per 56 day\u002Feight week period, but no more than approximately 2 ml\u002Fkg of blood at any one time.",[16,20,25,9],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Tumor Tissue Collection","Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[16,20,9],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Cyst Fluid","Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[20],[43,48],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Kenneth Yu, MD","CONTACT","646-888-4188","yuk1@mskcc.org",{"name":49,"role":45,"phone":50,"phoneExt":10,"email":10},"David Kelson, MD","646-888-4179",[52,69,80,95,106,117,126,134,144,153,164,179,191],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Memorial Sloan Kettering Monmouth (All protocol activities)","RECRUITING","Middletown","New Jersey","07748","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-74.11709,40.39428,{"lat":64,"lon":63},[67],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},"Kenneth Yu, MD, M.Sc.",{"facility":70,"status":54,"city":71,"state":56,"zip":72,"country":58,"countryCode":59,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Memorial Sloan Kettering Bergen (All protocol activities)","Montvale","07645",{"type":61,"coordinates":74},[75,76],-74.02292,41.04676,{"lat":76,"lon":75},[79],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":58,"countryCode":59,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Cold Springs Harbor Laboratory (Specimen Analysis)","NOT_YET_RECRUITING","Cold Spring Harbor","New York","11724",{"type":61,"coordinates":87},[88,89],-73.45679,40.87149,{"lat":89,"lon":88},[92],{"name":93,"role":45,"phone":94,"phoneExt":10,"email":10},"David Tuveson, MD, PhD","516-367-5246",{"facility":96,"status":54,"city":97,"state":84,"zip":98,"country":58,"countryCode":59,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)","Commack","11725",{"type":61,"coordinates":100},[101,102],-73.29289,40.84288,{"lat":102,"lon":101},[105],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":107,"status":54,"city":108,"state":84,"zip":109,"country":58,"countryCode":59,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Memorial Sloan Kettering Westchester (All protocol activities)","Harrison","10604",{"type":61,"coordinates":111},[112,113],-73.71263,40.96899,{"lat":113,"lon":112},[116],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":118,"status":119,"city":84,"state":84,"zip":120,"country":58,"countryCode":59,"cosmosGeoPoint":121,"geoPoint":125,"contacts":10},"New York University","ACTIVE_NOT_RECRUITING","10010",{"type":61,"coordinates":122},[123,124],-74.00597,40.71427,{"lat":124,"lon":123},{"facility":127,"status":54,"city":84,"state":84,"zip":128,"country":58,"countryCode":59,"cosmosGeoPoint":129,"geoPoint":131,"contacts":132},"Memorial Sloan - Kettering Cancer Center","10021",{"type":61,"coordinates":130},[123,124],{"lat":124,"lon":123},[133],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":135,"status":54,"city":84,"state":84,"zip":136,"country":58,"countryCode":59,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},"Memorial Sloan Kettering Basking Ridge (All protocol activities)","10065",{"type":61,"coordinates":138},[123,124],{"lat":124,"lon":123},[141,142],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},{"name":143,"role":45,"phone":10,"phoneExt":10,"email":10},"S",{"facility":145,"status":82,"city":84,"state":84,"zip":136,"country":58,"countryCode":59,"cosmosGeoPoint":146,"geoPoint":148,"contacts":149},"Weill Cornell Medical Center",{"type":61,"coordinates":147},[123,124],{"lat":124,"lon":123},[150],{"name":151,"role":45,"phone":152,"phoneExt":10,"email":10},"David Lyden, MD","212-746-6565",{"facility":154,"status":54,"city":155,"state":84,"zip":156,"country":58,"countryCode":59,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Memorial Sloan Kettering Nassau (All protocol activities)","Rockville Centre","11553",{"type":61,"coordinates":158},[159,160],-73.64124,40.65871,{"lat":160,"lon":159},[163],{"name":68,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":165,"status":82,"city":166,"state":10,"zip":167,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Sha'are Zedek Medical Center","Jerusalem","91031","Israel","IL",{"type":61,"coordinates":171},[172,173],35.21633,31.76904,{"lat":173,"lon":172},[176],{"name":177,"role":45,"phone":178,"phoneExt":10,"email":10},"Ephrat Levy-Lahad, PhD","646-497-2600",{"facility":180,"status":82,"city":181,"state":10,"zip":10,"country":168,"countryCode":169,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Weizmann Institute of Science","Rehovot",{"type":61,"coordinates":183},[184,185],34.81199,31.89421,{"lat":185,"lon":184},[188],{"name":189,"role":45,"phone":190,"phoneExt":10,"email":10},"Avigdor Scherz, PhD","972 8-934-2111",{"facility":192,"status":54,"city":193,"state":10,"zip":10,"country":168,"countryCode":169,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Sheba Medical Center","Tel Litwinsky",{"type":61,"coordinates":195},[196,197],34.84588,32.05096,{"lat":197,"lon":196},[200],{"name":201,"role":45,"phone":202,"phoneExt":10,"email":10},"Talia Golan, MD","03-5303295",{"type":204,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[206,208,210],{"name":192,"class":207},"OTHER_GOV",{"name":209,"class":6},"Weill Medical College of Cornell University",{"name":180,"class":6},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460",false,"NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,"ALL","18 Years",{"count":222,"type":223},700,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[227,228,229,230],"Pancreatic Cancer","Pancreatic Diseases","Pancreatitis","Pancreatic Cyst",[232],"17-257","2025-12-01",{"date":235,"type":236},"2025-12-02","ACTUAL",{"date":238,"type":236},"2017-10-30",{"date":240,"type":223},"2026-10-30",{"name":5,"class":6},13]